SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-503201"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-503201" > Izokibep :

  • Klint, SusanneAffibody AB, Solna, Sweden. (författare)

Izokibep : Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis

  • Artikel/kapitelEngelska2023

Förlag, utgivningsår, omfång ...

  • Taylor & Francis,2023
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-503201
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-503201URI
  • https://doi.org/10.1080/19420862.2023.2209920DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Psoriasis, an immune-mediated inflammatory disease, affects nearly 125 million people globally. The interleukin (IL)-17A homodimer is a key driver of psoriasis and other autoimmune diseases, including psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa, and uveitis. Treatment with monoclonal antibodies (mAbs) against IL-17A provides an improvement in the Psoriasis Area and Severity Index compared to conventional systemic agents. In this study, the Affibody(CIRCLED LATIN CAPITAL LETTER R) technology was used to identify and optimize a novel, small, biological molecule comprising three triple helical affinity domains, izokibep (previously ABY-035), for the inhibition of IL-17A signaling. Preclinical studies show that izokibep, a small 18.6 kDa IL-17 ligand trap comprising two IL-17A-specific Affibody domains and one albumin-binding domain, selectively inhibits human IL-17A in vitro and in vivo with superior potency and efficacy relative to anti-IL-17A mAbs. A Phase 1 first-in-human study was conducted to establish the safety, pharmacokinetics, and preliminary efficacy of izokibep, when administered intravenously and subcutaneously as single doses to healthy subjects, and as single intravenous and multiple subcutaneous doses to patients with psoriasis (NCT02690142; EudraCT No: 2015-004531-13). Izokibep was well tolerated with no meaningful safety concerns identified in healthy volunteers and patients with psoriasis. Rapid efficacy was seen in all psoriasis patients after one dose which further improved in patients receiving multiple doses. A therapeutic decrease in joint pain was also observed in a single patient with concurrent psoriatic arthritis. The study suggests that izokibep has the potential to safely treat IL17A-associated diseases such as psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa, and uveitis.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Feldwisch, JoachimAffibody AB, Solna, Sweden. (författare)
  • Gudmundsdotter, LindviAffibody AB, Solna, Sweden. (författare)
  • Bergstedt, Karin DillnerAffibody AB, Solna, Sweden. (författare)
  • Gunneriusson, ElinAffibody AB, Solna, Sweden. (författare)
  • Guthenberg, Ingmarie HoidenAffibody AB, Solna, Sweden. (författare)
  • Wennborg, AndersAffibody AB, Solna, Sweden. (författare)
  • Nyborg, Andrew C. C.ACELYRIN, Agoura Hills, CA USA. (författare)
  • Kamboj, Amol P. P.ACELYRIN, Agoura Hills, CA USA. (författare)
  • Peloso, Paul M. M.ACELYRIN, Agoura Hills, CA USA. (författare)
  • Bejker, DavidAffibody AB, Solna, Sweden. (författare)
  • Frejd, Fredrik Y.Uppsala universitet,Cancerprecisionsmedicin,Affibody AB, Solna, Sweden.;Affibody AB, Scheeles vag 2, SE-17165 Solna, Sweden.(Swepub:uu)freni195 (författare)
  • Affibody AB, Solna, Sweden.ACELYRIN, Agoura Hills, CA USA. (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:mAbs: Taylor & Francis15:11942-08621942-0870

Internetlänk

Hitta via bibliotek

  • mAbs (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy